Neo Ivy Capital Management Buys 3,865 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Neo Ivy Capital Management boosted its stake in Thermo Fisher by 426.1% in Q3, buying 3,865 shares to own 4,772 shares valued at about $2.315 million.
• Thermo Fisher beat quarterly estimates, reporting $6.57 EPS versus $6.45 expected and $12.22 billion in revenue (up 7.2% year‑over‑year), and retains a "Moderate Buy" analyst consensus with an average target near $633.68.
• The company raised its quarterly dividend to $0.47 (annualized $1.88, ~0.4% yield), while CEO Marc N. Casper sold 5,000 shares for roughly $2.56 million, reducing his stake by about 3.9%.

Neo Ivy Capital Management increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 426.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,772 shares of the medical research company's stock after acquiring an additional 3,865 shares during the period. Neo Ivy Capital Management's holdings in Thermo Fisher Scientific were worth $2,315,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Highline Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock valued at $29,000 after buying an additional 33 shares during the last quarter. Cloud Capital Management LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $31,000. Capital A Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after purchasing an additional 66 shares during the last quarter. Elevation Wealth Partners LLC raised its position in Thermo Fisher Scientific by 35.1% during the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company's stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. Finally, Howard Hughes Medical Institute bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $33,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 3.3%

NYSE:TMO opened at $501.72 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The company has a market capitalization of $186.38 billion, a PE ratio of 28.28, a P/E/G ratio of 2.99 and a beta of 0.96. The firm's 50-day moving average price is $567.28 and its 200-day moving average price is $548.32. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. During the same quarter in the previous year, the firm posted $6.10 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 7.2% on a year-over-year basis. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Friday, March 13th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.70%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TMO. Citigroup raised their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a "buy" rating in a research note on Friday, January 30th. TD Cowen cut their target price on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a research note on Friday, January 30th. Evercore reiterated an "outperform" rating and set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. Finally, KeyCorp upgraded Thermo Fisher Scientific from a "sector weight" rating to an "overweight" rating and set a $750.00 target price on the stock in a report on Sunday, December 7th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $633.68.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.